

# Hypoglycemia in post-bariatric vs. non-bariatric pregnancy: incidence and effects on fetal growth

Published: 30-07-2024

Last updated: 21-12-2024

Determine the number of hypoglycemic events (fasting and postprandial) during post-bariatric pregnancies compared to non-bariatric pregnancies (with obese and healthy BMI) using continuous glucose monitoring and its effects on fetal growth.

|                              |   |
|------------------------------|---|
| <b>Ethical review</b>        | Approved WMO  |
| <b>Status</b>                | Pending   |
| <b>Health condition type</b> | Glucose metabolism disorders (incl diabetes mellitus) |
| <b>Study type</b>            | Observational invasive                                |

## Summary

### ID

NL-OMON56907

### Source

ToetsingOnline

### Brief title

Hypo-baby

### Condition

- Glucose metabolism disorders (incl diabetes mellitus)
- Foetal complications
- Gastrointestinal therapeutic procedures

### Synonym

hypoglycemia, low blood sugar

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Medisch Centrum Leeuwarden

**Source(s) of monetary or material Support:** Dexcom, Medisch Centrum Leeuwarden

## Intervention

**Keyword:** Continuous glucose monitoring, Hypoglycemia, Metabolic-bariatric surgery, Pregnancy

## Outcome measures

### Primary outcome

The main endpoint is the number of hypoglycemic events (fasting and postprandial) during post-bariatric pregnancies and non-bariatric pregnancies (with obese and healthy BMI).

### Secondary outcome

The secondary study parameters are neonatal birthweight, gestational weight gain, placental weight and histology, micronutrient deficiency, and number of hyperglycemic events. Other parameters are data from the patient file (age, ethnicity, comorbidities, pre-bariatric weight).

## Study description

### Background summary

Current research suggests hypoglycemia is common in pregnancies after metabolic-bariatric surgery (MBS) and may contribute to fetal growth (FG) restrictions. However, the incidence of hypoglycemia is highly variable between studies, and evidence for its effects on FG is limited. Previous research into the extent in which hypoglycemia is responsible for FG restrictions after MBS often does not determine whether the incidence of hypoglycemia differs between trimesters, nor investigate other factors that might contribute to FG restrictions, such as gestational weight gain (GWG), placental quality, and post-BS micronutrient- and protein deficiencies. Additionally, more research into the incidence of hyperglycemia during pregnancy after MBS is important, as research suggests that it is increased in pregnancy after MBS.

### Study objective

Determine the number of hypoglycemic events (fasting and postprandial) during post-bariatric pregnancies compared to non-bariatric pregnancies (with obese and healthy BMI) using continuous glucose monitoring and its effects on fetal growth.

### **Study design**

This study is a prospective observational study, using continuous glucose monitoring.

### **Study burden and risks**

The burden for the subjects consists of the following: During each trimester of the pregnancy (at 12-14, 24 and 34 weeks), continuous glucose monitoring (CGM) will be done for 7 days, a blood sample will be taken, and the patient is weighted. Each subject will have 3 on site visits to place the CGM device. During the CGM, patients will fill out a patient diary on symptoms of hypoglycemia, food intake and daily activities. After the birth, the placenta is weighted. If the patient gives birth in the MCL, the placenta is send in for histological analysis. The risk for the subjects is low. During this study, we will determine the incidence of hypoglycemia in post-bariatric pregnancies and its potential effects on FG. The findings of the study can help us better our understanding of the effects of hypoglycemia on FG and thereby increase the number of uncomplicated pregnancies after bariatric surgery.

## **Contacts**

### **Public**

Medisch Centrum Leeuwarden

Henri Dunantweg 2  
Leeuwarden 8934 AD  
NL

### **Scientific**

Medisch Centrum Leeuwarden

Henri Dunantweg 2  
Leeuwarden 8934 AD  
NL

## **Trial sites**

## Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

### Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria: Pregnant, either after metabolic-bariatric surgery (Roux-en-Y gastric bypass or One anastomosis gastric bypass performed at CON, MCL with pre-surgery BMI >40, and post-BS total weight loss (TWL) of >20%), or without metabolic-bariatric surgery with BMI >40 or BMI between 18.5-24.9. At the time of inclusion, the subject must be between 6-10 weeks pregnant.

### Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:

- Diagnosis with type 1 or type 2 diabetes before the pregnancy, or diagnosis with type 1 or type 2 diabetes or GDM before the BS.
- Diagnosis with severe psychiatric or medical comorbidities known to potentially affect fetal growth (e.g. severe depression, lupus, chronic kidney disease).
- Continued smoking, alcohol consumption, or substance use throughout the pregnancy.
- Allergy for plasters.
- Multiple pregnancy.
- Pregnancy less than 12 months after bariatric surgery.
- Post-bariatric total weight loss of <20%

## Study design

### Design

Study type: Observational invasive

|                     |                                 |
|---------------------|---------------------------------|
| Intervention model: | Other                           |
| Allocation:         | Non-randomized controlled trial |
| Masking:            | Open (masking not used)         |

**Primary purpose:** Diagnostic

## Recruitment

|                           |             |
|---------------------------|-------------|
| NL                        |             |
| Recruitment status:       | Pending     |
| Start date (anticipated): | 01-12-2024  |
| Enrollment:               | 174         |
| Type:                     | Anticipated |

## Medical products/devices used

|               |    |
|---------------|----|
| Registration: | No |
|---------------|----|

## Ethics review

|                    |   |
|--------------------|---|
| Approved WMO       |   |
| Date:              | 30-07-2024  |
| Application type:  | First submission  |
| Review commission: | RTPO, Regionale Toetsingscie Patientgebonden Onderzoek (Leeuwarden) |

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

**In other registers**

| Register | ID             |
|----------|----------------|
| CCMO     | NL86830.099.24 |